Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia

Summary

To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in adults with primary hypercholesterolemia; To determine the safety of HS-25 (20mg) in subjects with LDL-C

Timeline

Start

2016-04-12

Primary completion

2018-04-20

Completion

2018-09-20

Drugs

Indications